Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

2(67%)

Phase Distribution

Ph early_phase_1

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 1Safety & dosage

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (33.3%)

Phase 12 (66.7%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NCT02431559

terminatedearly_phase_1

Intratumoral Microdosing of Motolimod in HNSCC

NCT04272333

terminatedphase_1

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

NCT02124850

Clinical Trials (3)

Showing 3 of 3 trials

NCT02431559Phase 1

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Completed

NCT04272333Early Phase 1

Intratumoral Microdosing of Motolimod in HNSCC

Terminated

NCT02124850Phase 1

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3